Pharmaceutical development follows a structured stage-gate process. The pipeline moves through distinct phases — Discovery, Candidate Selection, Preclinical, Phase I, Phase II, Phase III, Pre-launch, Post-launch, Mature product — with formal decision points governing progression.
Six critical decisions punctuate this journey:
| Decision Point | Full Name | Where It Falls |
| CSP | Candidate Selection Point | End of discovery |
| SPOC | Selection for Proof of Concept | Around candidate selection |
| POC | Proof of Concept | Phase I completion |
| DDP | Development Decision Point | Phase II |
| FDP | Full Development Point | Phase II/III transition |
| SDP | Submission Decision Point | Phase III completion |
At each decision point, CI provides a different type of intelligence and answers fundamentally different questions. The investment changes, the sources shift, the deliverables evolve. What doesn't change is the core purpose: reduce uncertainty and improve the quality of the decision being made.
The intelligence requirements that drive this process — Key Intelligence Topics and Key Intelligence Questions — serve as the foundation row beneath every deliverable at every stage. KITs/KIQs, the collection plan, vendor management, analysis, and data storage all run continuously underneath the lifecycle-specific deliverables. Without that foundation, you're collecting data without direction. For the full KIQs methodology, see Key Intelligence Questions: The Foundation of Any CI Program.
Pharma Competitive Intelligence: The Definitive Guide
In the earliest stages, CI operates at the Asset Level — intelligence at the individual compound level during early research and development.
The intelligence focus is broad. You're trying to understand who else is working in the therapeutic space, what mechanisms of action are being explored, and whether the competitive landscape supports continued investment.
of a mid-size pharmaceutical company describes this stage from the perspective of a smaller company developing new compounds: the work begins with target validation and building a Target Product Profile, then mapping the competitive landscape and monitoring it over what can be a 10- to 15-year development cycle. For a small pharma company, this intelligence was historically expensive and slow — you relied on external vendors for competitive analysis, waited weeks for reports, and the findings were often stale by the time they arrived. AI has changed that calculus. His team can now establish strategy, test different assumptions, and compare scenarios at a fraction of the former cost and time.
But whether you're a 15-person CI team or a scientist doing competitive intelligence without knowing it, the questions at this stage are fundamentally mapping questions:
You're not yet trying to outmaneuver a specific competitor. You're determining whether the field is crowded, whether your mechanism is differentiated, and whether continued investment is warranted.
Budget: 100–300K CHF | Resource: 0.1–0.3 FTE per early-stage asset
The deliverables at this stage are foundational: competitive pipelines and landscapes, key event timelines, clinical trial trackers, product profile comparisons, conference coverage, and secondary monitoring. Beneath all of these sits the KIT/KIQ framework — the intelligence requirements that determine what gets tracked and why.
The CI investment is modest because the decisions are binary: continue or don't. But even here, the intelligence has to be rigorous enough to prevent advancing a compound into a saturated competitive space.
Phase II–III is where CI intensity escalates dramatically. The questions get more specific, the stakes get higher, and the requirement shifts from landscape mapping to competitor-by-competitor tactical analysis.
The head of a CI Center of Excellence at a top-10 pharma company, describes the scope of pipeline intelligence at this stage: tracking sponsors, molecules, mechanisms of action, trial design, inclusion and exclusion criteria, and organizational decision-making. "We work with teams from the bench to the board," he says. That's the range CI has to cover during clinical development — from the granular details of a competitor's Phase II design to the strategic implications for portfolio decisions at the board level.
CI delivers maximum ROI in clinical development when it prevents a bad investment or enables a better clinical design. The three cases I described at the beginning of this article all occurred at this stage — one company that failed to do adequate CI and lost everything, one that used CI to make a $30 million save, and one that used competitor intelligence to strengthen its own clinical protocol.
The difference between these outcomes isn't luck. It's the quality and depth of CI applied at the right decision point.
The deliverable set from Phase II/III carries forward but the intelligence requirements deepen. The budget remains in the 100–300K CHF range at 0.1–0.3 FTE, but as the asset approaches Phase III completion and the Full Development Point, investment begins scaling toward pre-launch levels.
From mid-development onward, CI questions span clinical, regulatory, IP, manufacturing, and commercial teams. No single function can answer them alone — and this cross-functional nature is a defining characteristic of pharma CI.
Formulation and drug delivery: What alternative routes of administration are competitors exploring? How does formulation strategy enable reaching new patients? What compliance issues exist with current dosage forms, and what new forms are competitors developing?
Intellectual property: What's the patent portfolio strategy compared to competitors'? What's the patenting situation for new clinical indications? What exclusivity status and extensions exist by region? What freedom to operate do we have? What supplementary protection certificates have been filed?
Regulatory and data protection: What's the pediatric exclusivity plan? What submission and approval timelines do competitors face? What bio-equivalence requirements apply to generic entries?
For organizations tracking generic competitors, the regulatory dimension gets particularly detailed. Four main application types — Article 10.1 (abridged), Article 10.3 (hybrid), Article 10a (bibliographic), and Mixed Applications — each with specific data exclusivity calculations and bioequivalence requirements.
You need to look at the complete picture to understand what's going on. In pharma CI, that picture always spans multiple functions and multiple regulatory jurisdictions.
As development moves toward filing and launch, CI pivots to a new set of questions: how will the product compete on value, price, and access?
Building the competitive value proposition:
Monitoring competitor access strategies:
This stage maps directly to the commercial inputs framework. During Phase 2 preparation, CI supports patient journey mapping and brand vision. During Phase 3, it feeds into value matrix development, HE&OR models, and clinical endpoint selection. During filing preparation, it validates value dossiers, confirms pricing and reimbursement strategy, and supports promotional communication planning.
There's something CI teams often miss here. A competitor's advantage may not be clinical superiority. It may be operational simplicity, better patient support, or a more compelling access strategy. Effective CI maps competitor positioning across multiple layers — from table stakes (meeting specifications, regulatory compliance) through functional value (product quality, innovation) to ease of doing business (time savings, responsiveness, expertise). The full picture matters.
The 24 months before launch represent the most CI-intensive period in a drug's lifecycle.
Budget: 250K–1M CHF | Resource: 0.3–0.5 FTE
Deliverables expand to include everything from the clinical development phase plus: early warning systems, competitor lifecycle management intelligence, competitive simulations (war games), FMEA/CTA (competitive threat assessments), deep dives, Gx and biosimilar tracking, litigation monitoring, guidelines intelligence, and internal network coordination.
Launch readiness operates across three workstreams:
Shape the Market (from –24 months): National KOLs identified and high prescribers engaged. Health authority influencer mapping at –18 months. Regional KOLs, advisory boards, medical education, advocacy plan, market access strategy at –12 months. HEOR publications ready, value dossier adapted locally at –6 months.
Shape the Brand: Situation analysis and global brand strategy at –24 months. Local brand strategy at –12 months. Final physician visual aid and promotional materials at –6 months.
Shape the Organization: MSL staffing plan at –24 months. MSLs calling on KOLs at –12 months. Full marketing team and field force trained at –6 months.
The launch window exposes a fundamental problem with traditional CI. Manual news monitoring fails at precisely the moment it matters most, because of six structural limitations:
At launch intensity, these aren't minor inconveniences. They're mission-critical failures. A competitor's Phase III readout that drops on a Friday evening can shift market dynamics before your team sees it Monday morning.
AI-powered CI addresses this directly: 24/7 automated monitoring with alerts in under 20 minutes, any-language coverage, personalization for each stakeholder — at roughly 60% lower cost. During the launch window, when competitive moves can shift market share within weeks, that speed differential is a competitive necessity.
One of the most consequential questions CI must answer: should we accelerate, pivot, or accept our position in the competitive sequence?
A BCG study of 29 drug classes with novel mechanisms launched after 2010 — 104 products — provides the evidence. When the value captured by a first-to-launch, best-in-class drug is set at 100%:
| Position | Value Captured |
| 1st + Best therapeutic profile | 100% |
| 1st + Medium therapeutic profile | 82% |
| 1st + Lowest therapeutic profile | 54% |
| 2nd + Best therapeutic profile | 38% |
| 3rd + Best therapeutic profile | 64% |
| 4th+ products | 9–19% |
The most dramatic finding: a second-to-launch product with the best therapeutic profile now captures only 38% of first-and-best value — a 50-percentage-point decline from the prior analysis. First-to-launch with merely a medium profile captures more than twice as much value as the best-in-class fast follower.
Oncology strongly favors first-to-launch. Ibrutinib's nearly four-year head start in BTK inhibitors created an incumbent advantage that followers couldn't overcome. Keytruda vs. Opdivo shows that even in near-simultaneous launches, the product demonstrating superior value over time pulls ahead.
Non-oncology markets are more forgiving. In diseases where patients cycle through multiple treatments — migraine, psoriasis, inflammatory conditions — later entrants can capture more value. Differentiation is harder, and no single entrant dominates.
Multiple-indication classes heavily penalize second entrants. Second-and-best captures only 20% of first-and-best value in multi-indication classes. First entrants win by expanding faster into additional indications.
For CI teams, the implications are concrete. You need precise intelligence on competitor development timelines — not just "Phase II" but enrollment rates, milestone progress, and projected filing dates. Relative therapeutic profiles. Indication expansion strategies. Speed-to-market options and the competitive cost of delay. The data is clear: speed is paramount, and CI must inform whether speed is achievable.
Disruptive dynamics add another dimension. Technologies like mRNA follow exponential rather than linear growth curves — deceptive early, disruptive later. CI has to track not only existing competitors but emerging technologies that may upend the entire therapeutic approach.
Loss of exclusivity demands a fundamentally different type of CI. The competitive landscape shifts from a handful of branded competitors to potentially dozens of generic entrants across a complex, multi-tiered value chain.
Budget: 200–750K CHF | Resource: 0.2–0.4 FTE
The deliverables at this stage center on competitor lifecycle management and Gx/biosimilar CI: manufacturing intelligence, regulatory routes and strategies, vertical structures, legal basis for generic entry, and marketing authorization tracking.
Generic intelligence requires mapping a multi-tiered value chain fundamentally different from branded competition:
In mature blockbuster markets, the numbers are staggering: an average of 83 players per blockbuster active ingredient across EU-15 markets. The key generic objective is first to market — a necessary condition for long-term market share. CI has to identify who will get there among those dozens of players.
White tablet intelligence and biosimilar intelligence work differently. White tablets have high player counts and excessive noise — the challenge is identifying signal. Biosimilars have fewer players but dramatically higher complexity in characterization, production, clinical requirements, and regulatory hurdles.
The handling principle applies across both: systematic and consistent information handling is the key to success. One information pool accessible to all departments. Validated sources. Controlled distribution. Department-specific outputs.
Investment at LOE: 200–750K CHF and 0.2–0.4 FTE per brand, with geographic scope expanding to include emerging markets as generic threats emerge from India, China, and Brazil.
The lifecycle narrative above isn't a sequence of disconnected phases. It's a continuous strategic thread.
CI activities evolve across the cash flow curve:
Responsibility shifts from the Global Program Team (early development) to the Global Brand Team (launch through maturity) to Local teams (LOE and beyond).
Across the entire lifecycle, competitive preparedness follows a structured process:
Steps 3, 4, and 5 form a cyclical core, with continuous CI monitoring running beneath the entire process.
a senior strategy executive at a top-10 pharma company makes a point that connects directly to lifecycle CI: "I want AI to do the data gathering so I can spend time on strategic thinking — framing those strategic choices, scenarios, implications." His team built what they call the "a centralized intelligence system" — uploading all their intellectual property into a centralized AI knowledge system so that when a strategist approaches a new problem, they approach it with the full weight of the organization's accumulated knowledge. "Your best shot is your first shot."
The logic applies at every stage gate. During early development, the strategic questions are about landscape and differentiation — is this space worth entering? During clinical development, they become more tactical — how does a competitor's trial design signal their positioning? During pre-launch, they turn commercial — what messaging will a competitor lead with, and how do we counter it?
The AI shift doesn't change which questions matter. It changes how quickly and thoroughly they can be answered. A CI team that spent weeks compiling a competitive landscape during Phase II can now generate the same baseline in days — and spend the recovered time on the strategic interpretation that actually moves decisions.
That's the compounding effect applied to the lifecycle. Intelligence gathered at Phase II doesn't disappear when the asset reaches Phase III. It builds. Patterns detected during clinical development inform the competitive threat assessment at pre-launch. Launch intelligence shapes the LOE strategy. Each cycle of knowledge-learning-agency makes the next one sharper.
There's a powerful insight from strategic management that many CI programs underweight: excellent execution with mediocre strategy will beat mediocre execution with excellent strategy. CI has to assess not just competitor strategy but competitor execution capability — their culture, capabilities, and resources.
Understanding what a competitor celebrates, how they make decisions, what their capabilities are, and what resources they can bring to bear is often more predictive of competitive outcomes than analyzing their strategy in isolation.
With AI-augmented CI, intelligence compounds over time through a knowledge-learning-agency flywheel. Each cycle sharpens the next.
Knowledge captures and connects signals — a congress pricing rumor, a patent filing in an adjacent class, an FDA draft guidance shift, an earnings call language change. Individually routine. Collectively, they point to a competitor's strategic pivot.
Learning builds organizational capabilities — familiarity transfers, preferences get codified, each new tool takes less ramp-up time.
Agency acts on those capabilities — patterns detected months earlier than traditional methods.
The effects are concrete: adoption gets faster, outputs get better, time to quality compresses. The operating model shifts from batch processing to continuous intelligence — and the competitive advantage grows with every cycle.
CI is not a phase. It's a continuous thread from the first patent filing to the last day of exclusivity. With AI, that thread compounds in value over time. The organizations that understand this — and invest accordingly — are the ones building sustainable competitive advantage.
At the pre-clinical stage, before Phase I. Even at the earliest point, understanding who else is in the therapeutic space, what mechanisms they're pursuing, and whether the landscape supports continued investment is essential. The investment is modest — 0.1–0.3 FTE, 100–300K CHF — but the decisions it informs are foundational.
It evolves across four dimensions: scope (from landscape mapping to competitor-specific tactical analysis), investment (from 100–300K CHF to 250K–1M CHF), deliverables (from monitoring and landscapes to war games, scenario planning, and rapid response), and geography (from EU/US to global including emerging markets). The questions get more specific and the stakes higher at each phase.
A structured evaluation of competitor actions and their potential impact on brand or portfolio strategy. It's step 3 in the 6-step Competitive Readiness process — following a trigger event and deep dive, leading into competitive simulations and refined action plans.
100–300K CHF and 0.1–0.3 FTE per asset during Phase II/III. 250K–1M CHF and 0.3–0.5 FTE per brand at Pre-Launch and Launch. 200–750K CHF and 0.2–0.4 FTE at LOE. The intensity depends on the commercial value of the asset and the competitive threat level.
Not always, but the advantage has substantially increased. The BCG study found that second-to-launch with the best therapeutic profile now captures only 38% of first-and-best value — a 50-point decline from prior analysis. Later entrants can still capture value by launching a best-in-class profile within two years, expanding the addressable market, using an alternative modality, or innovating on market access.
Three ways. First, automating routine monitoring — 24/7 coverage, alerts in under 20 minutes, any-language support at roughly 60% lower cost. Second, creating compounding analytical value through a knowledge-learning-agency flywheel where intelligence from each development phase builds on the last. Third, enabling continuous intelligence that replaces periodic reports with real-time decision support. The real shift is from batch reporting to continuous intelligence embedded in both strategic and in-year decision-making.
A specialized CI discipline focused on tracking generic competitors across a multi-tiered value chain. It encompasses monitoring, early warning of regulatory submissions, launch preparation tracking, capacity estimation, price forecasting, and legal support. The key objective: identify who will be first to market among potentially 80+ generic players per blockbuster product.